Posted on:Weil in the News
Weil advised Eli Lilly and Company in its $1.1 billion acquisition of Dermira, Inc., a developer of new therapies for chronic skin conditions. The transaction closed on February 20, 2020.
The Weil team that advised Eli Lilly was led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and included Mergers & Acquisitions counsel Aileen Kim and Mergers & Acquisitions associates Sam Hulsey and Adena Kleiner. The team also included Tax partner Helyn Goldstein; Executive Compensation & Benefits partners Amy Rubin and Jennifer Haydel Britz; Technology & IP Transactions partner Jeffrey Osterman; Tax counsel Eric Remijan; Environmental counsel John O’Loughlin; Executive Compensation & Benefits associate Daniel Rios; and Technology & IP Transactions associates Kane Wishart and Caleb Small (Not Yet Admitted in New York).